Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
SPPI closed down 0.61 percent on Wednesday, November 22, 2017, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|See historical SPPI trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 22||NR7||Range Contraction||0.00%|
|Nov 21||Upper Bollinger Band Walk||Other||-0.61%|
|Nov 20||Bollinger Band Squeeze||Range Contraction||3.03%|
|Nov 17||Bearish Engulfing||Bearish||1.03%|
|Nov 17||Bollinger Band Squeeze||Range Contraction||1.03%|
|Nov 16||New 52 Week Closing High||Bullish||-4.97%|
|Nov 16||Bollinger Band Squeeze||Range Contraction||-4.97%|
|Nov 15||Bollinger Band Squeeze||Range Contraction||0.20%|
|Nov 14||Stochastic Buy Signal||Bullish||4.79%|
|Nov 14||Bollinger Band Squeeze||Range Contraction||4.79%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SPPI news...
|52 Week High||21.95|
|52 Week Low||3.85|
|200-Day Moving Average||9.3864|
|50-Day Moving Average||15.9848|
|20-Day Moving Average||19.2735|
|10-Day Moving Average||19.285|
|Average True Range||1.0331|
|Chandelier Exit (Long, 3 ATRs )||17.9007|
|Chandelier Exit (Short, 3 ATRs )||21.1693|
|Upper Bollinger Band||20.3275|
|Lower Bollinger Band||18.2195|
|Percent B (%b)||0.7|
|MACD Signal Line||1.111|
|Market Cap||1.55 Billion|
|Num Shares||78.8 Million|
|Price-to-Earnings (P/E) Ratio||-19.70|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||20.60|
|Resistance 3 (R3)||20.61||20.33||20.45|
|Resistance 2 (R2)||20.33||20.10||20.32||20.40|
|Resistance 1 (R1)||20.01||19.96||19.87||20.00||20.35|
|Support 1 (S1)||19.41||19.50||19.27||19.40||19.05|
|Support 2 (S2)||19.13||19.36||19.12||19.00|
|Support 3 (S3)||18.81||19.13||18.95|
|Support 4 (S4)||18.80|